{{Rsnum
|rsid=2241145
|Gene=MMP2
|Chromosome=16
|position=55488288
|Orientation=plus
|GMAF=0.4931
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=MMP2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 23.1 | 53.8 | 23.1
| HCB | 13.3 | 64.4 | 22.2
| JPT | 34.1 | 50.0 | 15.9
| YRI | 23.8 | 58.7 | 17.5
| ASW | 0.0 | 0.0 | 0.0
| CHB | 13.3 | 64.4 | 22.2
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}

{{PMID|18560213}} association of the MMP-2 gene with the development of lacunar stroke. [[rs1030868]], [[rs2241145]], [[rs2287074]], [[rs2287076]], [[rs7201]] showed a significant association with small vessel infarcts (p < 0.05) and rs7201:g.C was identified as an independent risk factor by multivariable logistic regression analysis

{{PMID|19454611|OA=1
}} Matrix metalloproteinase-2 polymorphisms and breast cancer susceptibility.

{{PMID|20222942|OA=1
}} Variants of the Matrix Metalloproteinase-2 but not the Matrix Metalloproteinase-9 genes significantly influence functional outcome after stroke.

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}